Pulsenmore Ltd.: Pulsenmore Expands Its Fertility Platform into the UK
Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) has registered its home ultrasound system, Pulsenmore FC, with the UK's MHRA, allowing it to market the product in the UK and Northern Ireland. The system is designed for women undergoing IVF and fertility preservation treatments, enabling at-home monitoring. The UK fertility market saw over 100,000 treatment cycles in 2024, according to the HFEA. This expansion follows the company's recent European registration under the Medical Device Regulation (MDR
How this was made
The 30-second read
Why it matters
Regulatory clearance in the UK could unlock a new revenue stream and improve the company's growth outlook.
Market read
First‑time UK approval for Pulsenmore's fertility platform provides a material catalyst for the stock.
What to watch
Potential reimbursement hurdles and competition from established fertility device manufacturers.
Background
Pulsenmore, a NASDAQ‑listed health‑tech company, develops patient‑operated ultrasound systems for pregnancy and fertility monitoring.
Ticker impact
Pulsenmore received MHRA registration, enabling UK market entry for its fertility ultrasound system.
Potential upside as investors price in UK sales opportunity; short-term catalyst may drive modest price rise.
First-time UK approval is material for a micro‑cap health‑tech firm; however, commercial rollout timing and scale remain uncertain.
Market effects
Adds a new entrant to the women's health and fertility device space, may pressure peers to seek similar approvals.
Expands Pulsenmore's footprint into the UK, a market with >100,000 fertility cycles annually.
Demonstrates growing acceptance of remote‑ultrasound technology worldwide.
Counterpoint
UK market size may be limited and adoption could be slower than expected, dampening revenue upside.
Key entities
- CompanyPulsenmore Ltd.
Healthcare technology firm developing remote ultrasound solutions.
- RegulatorMHRA
UK Medicines and Healthcare products Regulatory Agency responsible for medical device approvals.
